Home - Yahoo! - Help

More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials | Reports

Recent Events Aug  2 Conference call: Noven Pharmaceuticals, Inc. Earnings (Q2) Location 11960 S.W. 144th Street Miami, FL 33186 Phone: (305) 253-5099 Fax: (305) 251-1887 Employees (last reported count): 232 Financial Links  ·Top Institutional Holders  ·Top Mutual Fund Holders  ·Analyst Upgrade/Downgrade History  ·Historical Quote Data  ·Raw SEC Filings at sec.gov Competitors:  ·Sector: Healthcare  ·Industry: Biotechnology & Drugs Company Website  ·Home Page  ·Search Yahoo! for related links... Index Membership  ·S&P 600 SmallCap Ownership · Insider and 5%+ Owners: 16% · Over the last 6 months:  · 3 insider sells; 76.0K shares   (2.1% of insider shares) · Institutional: 78% (93% of float) (281 institutions) · Net Inst. Buying: 206.0K shares (+1.16%) (prior quarter to latest quarter) More From Market Guide  ·Highlights  ·Performance  ·Ratio Comparisons

Business Summary Noven Pharmaceuticals, Inc. is engaged in the development and manufacture of advanced transdermal and transmucosal drug delivery products and technologies. Noven's principal commercialized products are transdermal drug delivery systems for use in hormone replacement therapy. Noven's first product was an estrogen patch for the treatment of menopausal symptoms marketed under the brand name Vivelle in the United States and Canada, and under the brand name Menorest in Europe and certain other markets. Noven's second-generation estrogen patch is marketed under the brand name Vivelle-Dot. Noven also developed a combination estrogen/progestin transdermal patch for the treatment of menopausal symptoms, which is marketed under the brand name CombiPatch in the United States, and under the brand name Estalis in Europe and certain other markets. More from Market Guide: Expanded Business Description Financial Summary Noven Pharmaceuticals develops and commercializes transdermal and transmucosal drug delivery systems, including transdermal estrogen delivery systems. For the six months ended 6/30/01, revenues rose 26% to $25.3 million. Net income rose 11% to $5.9 million. Revenues reflect increased sales of Estalis and the minimum fee payments related to the sales of Menorest. Earnings were partially offset by increased effective tax rate. More from Market Guide: Significant Developments Officers [Insider Trade Data] FY2000 Compensation Pay Exer Robert Strauss, 58 Chairman, Pres, CEO $782K $219K James Messiry, 58 VP andCFO 290K 239K Juan Mantelle, 42 VP, CTO 333K 1.2M Jeffrey Eisenberg, 35 VP, Gen. Counsel, Sec. --   --   Anthony De Padova, 57 VP, Clinical Research and Regulatory Affairs --   --   Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. More from Market Guide on Officers & Directors: Expanded List, Bios, Compensation, Options

Price and Volume 52-Week Low on 2-Apr-2001 $16.375 Recent Price $22.17  52-Week High on 30-Oct-2000 $64.25  Beta 1.01  Daily Volume (3-month avg) 535.2K Daily Volume (10-day avg) 312.0K Stock Performance big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max] 52-Week Change -46.9% 52-Week Change relative to S&P500 -28.8% Share-Related Items Market Capitalization $497.2M Shares Outstanding 22.4M Float 18.8M Dividends & Splits Annual Dividend none  Last Split none	Per-Share Data Book Value (mrq) $3.33  Earnings (ttm) $0.85  Earnings (mrq) $0.14  Sales (ttm) $2.03  Cash (mrq) $1.88  Valuation Ratios Price/Book (mrq) 6.66  Price/Earnings (ttm) 26.02  Price/Sales (ttm) 10.90  Income Statements Sales (ttm) $48.1M EBITDA (ttm) $5.75M Income available to common (ttm) $20.2M Profitability Profit Margin (ttm) 22.7% Operating Margin (ttm) 8.6% Fiscal Year Fiscal Year Ends Dec 31 Most recent quarter 30-June-2001	Management Effectiveness Return on Assets (ttm) 10.26% Return on Equity (ttm) 32.74% Financial Strength Current Ratio (mrq) 2.16  Debt/Equity (mrq) 0.01  Total Cash (mrq) $42.1M Short Interest As of 8-Aug-2001 Shares Short 360.0K Percent of Float 1.9% Shares Short (Prior Month) 543.0K Short Ratio 0.34  Daily Volume 1.05M
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.